Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiome/Astellas' Kynapid Approval Seems Likely For Limited Indication, If Additional Trial Holds Up

This article was originally published in The Pink Sheet Daily

Executive Summary

Atrial fibrillation drug has been languishing after "approvable" letter - but approval now seems in the cards for limited indication.

You may also be interested in...



Astellas Likely To Cede U.S. Rights to Vernakalant, Cardiome CEO Says

Cardiome Pharma will likely be announcing a change in ownership for the U.S. rights to the I.V. version of its cardiovascular drug vernakalant by the end of the first quarter, CEO Doug Janzen told analysts on an earnings call

Astellas Likely To Cede U.S. Rights to Vernakalant, Cardiome CEO Says

Analysts speculate that Merck will buy out Astellas' U.S. vernakalant rights in a move that would be positive for Cardiome.

Astellas Likely To Cede U.S. Rights to Vernakalant, Cardiome CEO Says

Analysts speculate that Merck will buy out Astellas' U.S. vernakalant rights in a move that would be positive for Cardiome.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel